Licensing status

Publication and contact information


Lung cancer

EPH receptor A2 (EPHA2)

Cell culture and mouse studies suggest inhibiting EPHA2 could help treat lung cancer. In a K-Ras (KRAS)-driven mouse model of lung cancer, Epha2 knockout decreased tumor burden and increased tumor cell apoptosis compared with no alteration. In cultured human non-small cell lung cancer (NSCLC) cells, an inhibitor of EPHA2 increased cell death compared with an inactive analog. In a mouse xenograft model of NSCLC, the inhibitor decreased tumor growth and increased tumor cell apoptosis compared with the analog or vehicle. Next steps could include developing inhibitors with higher specificity for EPHA2 or with increased bioavailability.
Daiichi Sankyo Co. Ltd. has the anti-EPHA2 antibody DS-8859a in Phase I testing to treat solid tumors.

SciBX 7(19); doi:10.1038/scibx.2014.557
Published online May 15, 2014

Patent and licensing status unavailable

Amato, K.R. et al. J. Clin. Invest.; published online April 8, 2014;
Contact: Jin Chen, Vanderbilt University School of Medicine, Nashville, Tenn.